The Association of Cigarette Smoking With Enhanced Platelet Inhibition by Clopidogrel  by Bliden, Kevin P. et al.
C
c
m
r
o
3
i
h
p
h
v
p
A
i
F
†
s
B
a
Journal of the American College of Cardiology Vol. 52, No. 7, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
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Objectives The purpose of this study was to examine the effect of cigarette smoking on the platelet response to clopidogrel.
Background Response variability to clopidogrel therapy has been demonstrated. Clopidogrel is metabolically activated by sev-
eral hepatic cytochrome P450 (CYP) isoenzymes, including CYP1A2. Cigarette smoking induces CYP1A2 and
may, therefore, enhance the conversion of clopidogrel to its active metabolite.
Methods Among 259 consecutive patients undergoing elective coronary stenting; 120 were on chronic clopidogrel therapy and
were not loaded; and 139 were clopidogrel naïve and were loaded with 600 mg. There were 104 current smokers
(CS) and 155 nonsmokers (NS). The adenosine diphosphate (ADP)-stimulated platelet aggregation (PA) was assessed
by conventional aggregometry. The ADP-stimulated total and active glycoprotein (GP) IIb/IIIa expression were as-
sessed with flow cytometry. Low PA was defined as the lowest quartile of 5 mol/l ADP-induced post-treatment PA.
Results Current smokers on chronic clopidogrel therapy displayed significantly lower PA and ADP-stimulated active GP
IIb/IIIa expression compared with NS (p  0.0008 for both). Similarly, CS treated with 600 mg of clopidogrel
displayed greater platelet inhibition and lower active GP IIb/IIIa expression compared with NS (p  0.05). In a
multivariate Cox regression analysis, current smoking was an independent predictor of low PA (p  0.0001).
Conclusion Clopidogrel therapy in CS is associated with increased platelet inhibition and lower aggregation as compared
with NS. The mechanism of the smoking effect deserves further study and may be an important cause of re-
sponse variability to clopidogrel therapy. (J Am Coll Cardiol 2008;52:531–3) © 2008 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.045R
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blopidogrel, a prodrug, is metabolized by 2 consecutive
ytochrome P450 (CYP)-dependent steps to its active
etabolite, which binds irreversibly to the platelet P2Y12
eceptor. The hepatic enzymes involved in the metabolism
f clopidogrel include CYP1A2, 2B6, 2C9, 2C19, and
A4/5 (1). High residual P2Y12 receptor reactivity is present
n selected patients who are treated with clopidogrel, and
igh on-treatment platelet reactivity to adenosine diphos-
hate (ADP), as measured by conventional aggregometry,
as been associated with post-percutaneous coronary inter-
ention (PCI) ischemic event occurrence (2). Recently,
atients on chronic clopidogrel therapy with high pre-PCI
DP-induced platelet aggregation were shown to be at
ncreased risk for long-term post-PCI ischemic events (3).
rom the *Sinai Center for Thrombosis Research, Baltimore, Maryland; and the
Medical Affairs Department, Daiichi Sankyo, Inc., Parsippany, New Jersey. This
tudy was supported by a grant from Daiichi Sankyo, Inc. and Sinai Hospital of
altimore, Maryland.c
Manuscript received January 3, 2008; revised manuscript received April 18, 2008,
ccepted April 30, 2008.Cigarette smoking is an inducer of CYP1A2 (4).
ecently, it has been suggested that smoking influences
he cardiovascular benefit of long-term therapy with
lopidogrel and aspirin in PCI patients (5). However,
here are no laboratory data to support a relation between
ncreased platelet inhibition by clopidogrel in current
mokers (CS) as compared with nonsmokers (NS).
oreover, there are no current data to demonstrate that
he aforementioned reported clinical effect of clopidogrel
reatment is related to better platelet inhibition in smok-
rs versus nonsmokers.
The objective of the study was to investigate the effect of
igarette smoking on the platelet response to clopidogrel as
easured by ADP-induced aggregation with conventional
urbidometric aggregometry in platelet-rich plasma and by
ow cytometry measurements of ADP-induced expression
f activation-dependent receptors in patients treated with
lective PCI. On the basis of previous observations, we
ypothesized that 5 mol/l ADP-induced aggregation would
e lower in CS after loading and maintenance doses of
lopidogrel compared with NS (6).
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We analyzed platelet function data
in 259 CS or NS undergoing elec-
tive PCI treated with clopidogrel
consecutively enrolled in clinical tri-
als at our center (7,8). There were
104 CS (smoking within 2 weeks of
PCI) and 155 NS (no smoking
within 1 year of PCI). Previous
smokers were excluded because the
influence of smoking on CYP1A2
activity is highly variable upon
smoking cessation (9) and the inter-
val between the last smoking event
and enrollment in the study was
inconsistent.
Patients who were on chronic clopidogrel therapy before
CI (n  120, 75 mg/day) were not loaded; and
lopidogrel-naïve patients (n  139) were loaded with 600
g immediately after PCI. Exclusion criteria were described
reviously (7,8). Blood was drawn before PCI from all
atients. In patients loaded with clopidogrel, platelet studies
ere also conducted either at 18 to 24 h after PCI in
atients not treated with eptifibatide (n 63) or at5 days
fter PCI in patients treated with eptifibatide (n  76).
latelet aggregation was assessed by conventional aggre-
ometry; ADP-stimulated total and active glycoprotein
GP) IIb/IIIa expression were assessed with flow cytometry
7,8).
esults
atient demographics and procedural characteristics were
imilar between the groups. However, CS had a greater
revalence of previous myocardial infarction (46% vs. 23%,
 0.005) and treatment of bifurcation lesions (12% vs.
%, p  0.005), whereas NS more often had diabetes (33%
s. 48%, p  0.01). No patients had been treated with
mmunosuppressants, antibiotics, or anti–human immuno-
eficiency virus agents that may influence CYP activity
ithin 2 weeks of study.
Current smokers on chronic clopidogrel therapy dis-
layed significantly lower 5 and 20 mol/l ADP-induced
latelet aggregation (32  12% vs. 44  13%, p  0.0001;
3  14% vs. 52  17%, p  0.008, respectively) and
DP-stimulated active GP IIb/IIIa expression compared
ith NS (7  4 mean fluorescence intensity vs. 19  18
ean fluorescence intensity, p  0.0007). Relative inhibi-
ion of platelet aggregation (IPA) was calculated in patients
eceiving a clopidogrel loading dose from the measured max-
mum platelet aggregation (MPA) where IPA [(MPApredose
MPApostdose)/MPApredose]  100%. Current smokers
reated with 600 mg of clopidogrel displayed greater IPA (5
mol/l ADP, 46  23% vs. 34  21% p  0.002 and 20
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
CS  current smokers
CYP  consecutive
cytochrome P450
GP  glycoprotein
IPA  inhibition of platelet
aggregation
MPA  maximum platelet
aggregation
NS  nonsmokers
PCI  percutaneous
coronary interventionmol/l ADP, 38 6% vs. 31 21%, p 0.04) and greaterelative inhibition of active GP IIb/IIIa expression com-
ared with NS (58  24% vs. 40  36%, p  0.05). An
nalysis of variance in patients on chronic clopidogrel
herapy demonstrated significantly lower 5 mol/l and 20
mol/l ADP-induced platelet aggregation in patients cur-
ently smoking 1/2 pack/day compared with NS and
atients currently smoking 1/2 pack/day (p  0.05) (Figs.
A and 1B). However, no significant differences in platelet
ggregation were observed between NS and CS smoking
1/2 pack/day.
A logistic regression analysis evaluated the impact of age,
ody mass index, diabetes, history of myocardial infarction,
ypertension, smoking status, and use of calcium antago-
ists, angiotensin-converting enzyme inhibitors, beta block-
rs, and statins on low post-treatment platelet aggregation
29%), defined as the lowest quartile of 5 mol/l ADP-
nduced platelet aggregation after clopidogrel therapy
Figure 1 ADP-Induced Platelet Aggregation
Box-and-whisker plot demonstrating post-treatment 5 (A) and 20 mol/l (B)
ADP-induced platelet aggregation as measured by light transmittance aggre-
gometry in nonsmokers (NS), current smokers (CS) smoking 1/2 pack/day,
and CS smoking 1/2 pack/day on chronic clopidogrel therapy. The central
box represents the values between the lower and upper quartiles, and the mid-
dle line is the median. The vertical line extends from the minimum to the max-
imum value, excluding outside values, which are displayed as separate points.
*p  0.05 for mean post-treatment platelet aggregation in CS smoking 1/2
pack/day compared with NS and CS smoking 1/2 pack/day.
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August 12, 2008:531–3 Smoking and Clopidogrel ResponseMedCalc Software, Mariakerke, Belgium). Current smok-
ng was the only variable significantly associated with low
ost-treatment platelet aggregation (odds ratio 2.63, p 
.007).
iscussion
he current analysis demonstrates a positive relation be-
ween current cigarette smoking and the enhancement of
he antiplatelet effect of clopidogrel administered to patients
ndergoing nonemergent coronary stenting. The relation
etween clopidogrel effect and current smoking was robust
n patients who were treated with a chronic maintenance
ose who were not loaded and in clopidogrel-naïve patients
dministered a 600-mg loading dose. The measurements of
latelet function used in our study are the most widely
escribed in the literature to assess the platelet response to
lopidogrel.
In the current study, in a multivariate analysis, we
emonstrated the significant effect of smoking on platelet
unction during clopidogrel therapy. These data are consis-
ent with the first observations of clopidogrel response
ariability in a study of 96 patients treated with 300 mg of
lopidogrel for elective coronary artery stenting (10). In the
atter investigation, we observed that 13% of the non-
esponders to clopidogrel were smokers as compared with
8% of the responders. In addition, Matetzky et al. (6)
eported that smokers were less often clopidogrel resistant.
inally, we observed that the amount of cigarettes smoked
ppeared to affect the response to clopidogrel.
In patients who smoked 1/2 pack/day treated with
hronic clopidogrel therapy, we did not observe an effect of
moking on ADP-induced platelet aggregation. It has been
uggested that cigarette smoking induces CYP1A2 activity
n a “dose-related” manner. In normal volunteers, CYP1A2
ctivity was increased relative to the number of cigarettes
moked per day, with a 1.22-, 1.47-, 1.66-, and 1.72-fold
ncrease in activity observed with smoking 1 to 5, 6 to 10, 11
o 20, and 20 cigarettes/day, respectively (11).
The data from our study are consistent with these
revious observations and suggest that the number of
igarettes smoked is an important consideration when
valuating potential smoking effects on PA in clopidogrel-
reated patients. Our hypothesis is that significant cigarette
moking (i.e., 10 cigarettes/day) affects platelet inhibition
n clopidogrel-treated patients through the induction of
YP1A2. The aforementioned results may provide an
xplanation for the cardiovascular event reduction observed
n smokers compared with NS treated with clopidogrel plus
spirin in a subanalysis of the CREDO (Clopidogrel for the
eduction of Events During Observation) trial (5). Ktudy limitations. Because our study was a post-hoc anal-
sis, we cannot rule out the influence of selection bias or
ther variables that may affect the hepatic metabolism of
lopidogrel and were not recorded in the case report form
uch as use of caffeine, proton pump inhibitors, or herbal
gents. To address these concerns, a well-controlled pro-
pective study is needed.
onclusions
igarette smoking influences platelet responsiveness to
lopidogrel. The mechanism of the effect deserves further
tudy and may further elucidate the causes of response
ariability to clopidogrel and the clinical efficacy of clopi-
ogrel in specific patient groups.
eprint requests and correspondence: Dr. Paul A. Gurbel, Sinai
enter for Thrombosis Research, Shapiro Building, Room 209,
401 West Belvedere Avenue, Baltimore, Maryland 21215.
-mail: pgurbel@lifebridgehealth.org.
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